|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
GENE THERAPY
From the Department of Pediatrics and Pathology,
University of Pennsylvania Medical Center; The Children's Hospital of
Philadelphia; the Department of Neurology, Allegheny University of the
Health Sciences; and the Institute for Human Gene Therapy, University
of Pennsylvania, Philadelphia, PA; and Avigen, Alameda, CA.
Recent data demonstrate that the introduction into skeletal muscle
of an adeno-associated viral (AAV) vector expressing blood coagulation
factor IX (F.IX) can result in long-term expression of the transgene
product and amelioration of the bleeding diathesis in animals with
hemophilia B. These data suggest that biologically active F.IX can be
synthesized in skeletal muscle. Factor IX undergoes extensive
posttranslational modifications in the liver, the normal site of
synthesis. In addition to affecting specific activity, these
posttranslational modifications can also affect recovery, half-life in
the circulation, and the immunogenicity of the protein. Before
initiating a human trial of an AAV-mediated, muscle-directed approach
for treating hemophilia B, a detailed biochemical analysis of F.IX
synthesized in skeletal muscle was carried out. As a model system,
human myotubes transduced with an AAV vector expressing F.IX was used.
F.IX was purified from conditioned medium using a novel strategy
designed to purify material representative of all species of rF.IX in
the medium. Purified F.IX was analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), N-terminal
sequence analysis, chemical Hemophilia B is an X-linked hemorrhagic disorder
characterized by a functional deficiency of clotting factor IX (F.IX).
The current treatment for hemophilia B is based on replacement using plasma-derived or recombinant F.IX, either in response to bleeding episodes or prophylactically. The short half-life of the protein, requiring multiple intravenous injections, the expense of these products, and, in the case of plasma-derived concentrates, the risk for
blood-borne disease, are all disadvantages of the current protein-based
therapy.1-8
The development of somatic gene therapy for F.IX deficiency is an
attractive therapeutic option. The continuous presence in the
bloodstream of amounts of F.IX as low as 1% of normal has been shown
to be clinically relevant in terms of preventing or substantially
reducing the frequency of spontaneous bleeds into the joints, soft
tissues, or intracranial space.9,10 Factor IX is normally
synthesized in the liver, but from a gene therapy standpoint, there is
a strong motivation for evaluating alternative target tissues in this
population because of the high prevalence of viral hepatitis
(approximately 90%) among adults with severe hemophilia.11-13
Skeletal muscle has been extensively tested as a target tissue for gene
delivery.14,15 The transfer of foreign DNA into muscle
cells by viral or nonviral vectors results in efficient and stable
expression of a variety of transgenes.16-20
Adeno-associated virus 2 (AAV) is a single-stranded DNA virus of 4.7 kb, which was developed as a transducing vector capable of long-term
expression in nondividing cells such as liver and skeletal
muscle.16,21-23 Previous reports showed long-term
expression of therapeutic levels of F.IX in small and large animal
models of hemophilia B treated with intramuscular injection at multiple sites of an AAV vector encoding human or canine F.IX,
respectively.24,25 The canine hemophilia B
model26 allowed us to determine that the transgene product
(canine factor IX) is biologically active based on shortening of the
whole blood clotting time and of the activated partial thromboplastin time.
Factor IX is a vitamin K-dependent glycoprotein synthesized as a
precursor molecule of 461 amino acids. It undergoes extensive posttranslational modification, including cleavage and removal of the
pre-pro leader sequence of 46 amino acids; As part of the preclinical studies designed to assess the potential
efficacy of an AAV-mediated, muscle-directed approach, we sought to
analyze posttranslational modifications of F.IX synthesized in human
muscle. In this study, we have used a model system consisting of human
myotubes in culture, transduced with a recombinant AAV vector
expressing human F.IX. The myotube-synthesized protein has been
isolated from conditioned medium and characterized functionally and
biochemically. These data indicate that the material synthesized in
human myotubes is similar to plasma-derived (liver-synthesized) F.IX.
Production and purification of recombinant
adeno-associated virus
Transduction of human myotubes
Immunofluorescence staining of primary culture myotube cells Characterization of human myotubes was carried out using a rabbit anti-desmin monoclonal antibody (Sigma Chemical, St Louis, MO) and, for detection, an anti-rabbit IgG fluorescein-conjugated antibody (DAKO, Carpinteria, CA). Human factor IX was stained using a goat anti-human FIX antibody and, for detection, an anti-goat IgG rhodamine-conjugated antibody (Chemicon International, Temecula, CA).Purification of myotube-expressed recombinant F.IX from conditioned media Culture medium conditioned by AAV-hF.IX transduced myotubes was thawed at 37°C and mixed with benzamidine (5 mM) and soybean trypsin inhibitor (10 µg/mL media) and loaded onto a Q-Sepharose column (Amersham-Pharmacia, Piscataway, NJ) equilibrated in 20 mM Tris, pH 7.4-150 mM NaCl-2 mM benzamidine. Q-Sepharose was washed in 20 mM Tris, pH 7.4-150 mM NaCl-2 mM benzamidine and then with 20 mM Tris, pH 7.4-150 mM NaCl buffer before elution with 20 mM Tris, pH 7.4-750 mM NaCl.Eluted protein was applied to an immunoaffinity column prepared using a monoclonal antibody to the heavy chain of human F.IX (9EA; Enzyme Research Laboratories, South Bend, IN). All the bound protein was eluted with 150 mM NaCl-50 mM glycine pH 2.5. Fractions containing F.IX were pooled, dialyzed against distilled water or 20 mM HEPES, pH 7.4-150 mM NaCl, and concentrated by ultrafiltration on an Amicon apparatus (Amicon, Danvers, MA). SDS-PAGE and immunoblotting of myotube-synthesized F.IX Purified F.IX was separated by 7.5% SDS-PAGE and detected using silver staining (Bio-Rad, Hercules, CA). For immunoblotting, purified F.IX was separated by 7.5% SDS-PAGE and transferred to a nitrocellulose membrane (Amersham, United Kingdom) using an electroblot system (Bio-Rad, Hercules, CA) at 100 mA for 1 hour at 4°C. The membrane was incubated with a 2000 dilution mouse anti-human F.IX monoclonal antibody FXC008 (Boehringer Mannheim, Indianapolis, IN) as primary antibody and anti-mouse IgG peroxidase conjugate using a chemiluminescent substrate (Pierce, Rockford, IN) as a detecting antibody.Determination of specific activity of recombinant F.IX F.IX concentration was determined using a previously described enzyme-linked immunosorbent assay (ELISA)32 (capture antibody, polyclonal rabbit anti-human F.IX [DAKO]; detecting antibody, peroxidase-conjugated polyclonal goat anti-human F.IX [Affinity Biologicals, Hamilton, Ontario, Canada]). The functional activity was determined by a clotting assay using a modified one-stage factor assay incubating 50 µL human F.IX-deficient plasma (Organon Teknika, Durham, NC) with 50 µL automated activated partial thromboplastin time (aPTT) reagent (Organon Teknika, Durham, NC), and 50 µL test sample for 3 minutes at 37°C. Fifty µL of 25 mM CaCl2 was added, and time to clot formation was measured using a fibrometer. Lyophilized human plasma (Verify, Organon Teknika) was used as a reference standard. Purified F.IX was added to imidazole buffer in a series of dilutions calculated to achieve aPTTs in the midrange of the standard curve (50-70 seconds). Three samples, each purified from a separate transduction experiment, were analyzed by ELISA and clotting assay, and the results were used to calculate specific activity.To determine F.IX specific activity on conditioned media from transduced myotubes, lyophilized human plasma-derived F.IX (Mononine; Armour, Kankakee, IL) was added to conditioned media in the myotube culture to a final concentration of 1 IU/mL (5 µg/mL). A series of dilutions was calculated to achieve aPTTs in the midrange of the curve (50-70 seconds). Factor IX clotting activity was calculated after the exclusion of nonspecific clotting activity determined on the conditioned media from nontransduced myotubes. These results were used to determine specific activity obtained at different MOIs. In other experiments to establish the contribution of F.IX to the aPTT measurements on conditioned medium from transduced myotubes, the aPTT assay was performed before and after incubation at 37°C for 30 minutes with 2.5% anti-human IX monoclonal antibody FXC008 (Boehringer Mannheim, Indianapolis, IN). N-terminal sequence analysis Purified F.IX was eluted from the immunoaffinity column and dialyzed against water. The protein solution was subjected to amino acid microsequencing using an automated sequencer (173/A Microblotter; Applied Microsystems, Galveston, TX). However, -carboxyglutamic acid
is not detected on automated Edman degradation sequencing (ie, it
appears as a blank); thus efficiency of -carboxylation can be
estimated by comparing yields at these cycles to yields (in picomoles)
in previous and subsequent cycles. Uncarboxylated glutamic acid will be
evident as glutamic acid residues in the sequence.
Carbohydrate analysis Two types of analysis were performed on purified protein. First, enzymatic cleavage of N-linked glycans was carried out using recombinant N-glycosidase F (Boehringer Mannheim). Eight micrograms purified F.IX was incubated with 2.5 mU recombinant N-glycosidase F for 18 hours at 30°C in a mixture of 20 mM buffered sodium phosphate (pH 7.2)-10 mM sodium azide-50 mM EDTA-0.5% Nonidet P-40. Samples before and after N-glycosidase F treatment were analyzed by 7.5% SDS-PAGE; a change in apparent molecular weight suggested that glycan-linked residues were present and had been removed. In a second, more detailed analysis, N-linked oligosaccharide profiling was performed by fluorophore-assisted carbohydrate electrophoresis FACE (Glyko, Novato, CA). Each sample digestion was prepared with 100 µg purified protein. The samples were dried, resuspended in 25 µL of 50 mM phosphate buffer, pH 7.5, containing 0.1% SDS and -mercaptoethanol, and heated at 100°C for 5 minutes. Then 5 µL of 7.5% NP-40 was added. The samples were subjected to digestion with
5 mU N-glycosidase F (Glyko) for 16 hours at 37°C to release N-linked
carbohydrate. Sugars were then labeled with a fluorophore 8-aminonaphthalene 1,3,6-trisulfonate, disodium salt by reductive amination and separated by electrophoresis on a 21% polyacrylamide gel
at a constant current of 20 mA at 5°C for 1 hour. Visualized bands
were imaged and quantified using a FACE Imager ( excitation = 368
nm, emission = 470 nm)33 and compared to a purified plasma-derived F.IX control. In a similar digestion reaction, 100µg
purified protein was digested for 24 hours at 37°C with 2 mU
neuraminidase (Glyko, Novato, CA).
Tyrosine sulfation Tyrosine sulfation was analyzed using 35S-sulfate biosynthetic labeling of human myotubes or of Hep G2 cells transduced with AAV-hF.IX.34,35 Plates with comparable levels of F.IX production were selected, and medium was replaced with either sulfate-free medium or methionine-free medium (Cell & Molecular Technologies, Lavallette, NJ). After 30 minutes (sulfate) or 2 hours (methionine), media were replaced with media containing 35S-labeled H2SO4 or 35S-labeled methionine (NEN Life Science Products, Boston, MA). Sixteen hours later, conditioned medium was harvested, and F.IX was immunoprecipitated using a polyclonal antibody (A0300; DAKO). Samples were then split into 2 equal aliquots, and 1 aliquot was digested with recombinant N-glycosidase F. Both samples were then subjected to 7.5% SDS-PAGE. Proteins were transferred to a nitrocellulose membrane and visualized by autoradiography. Results were normalized based on 35S-methionine content determined by densitometry of F.IX bands. In another experiment, the same membrane was used for confirmation of these identified bands by immunoblotting as described above.Serine phosphorylation The extent of serine phosphorylation was analyzed using an anti-phosphoserine antibody. Purified F.IX samples, either plasma-derived or myotube-synthesized, were first treated with N-glycosidase F (Boehringer Mannheim) for 18 hours at 37°C in 20 mM sodium phosphate (pH 7.2)-10 mM sodium azide-50 mM EDTA-0.5% Nonidet P-40. Two ELISA determinations were then carried out side by side, one using as capture antibody a monoclonal anti-phosphoserine (PSR-45; Sigma), the other using a polyclonal rabbit anti-hF.IX (DAKO). Samples were applied in duplicate to plates, and a peroxidase-conjugated polyclonal goat anti-hF.IX (Affinity Biologicals, Hamilton, Ontario, Canada) was used as the detecting antibody.In vivo functional activity of myotube-synthesized F.IX To determine the in vivo functional activity of myotube-synthesized F.IX, we carried out 2 experiments in mice. Two micrograms commercially available plasma-derived (Mononine; Armour, Kankakee, IL) Chinese hamster ovary (CHO) cell-synthesized F.IX (Benefix; Genetic Institute, Cambridge, MA) and myotube-synthesized F.IX was injected intravenously by the tail vein in 10 mice (strain C57Bl/6; Jackson Laboratories, Bar Harbor, ME). Blood samples were collected by retro-orbital bleeding before injection and after 30 minutes, 6, 12, and 24 hours. In another group of 12 hemophilia B mice (strains C57Bl/6 and 129), the experiment was repeated using 10 µg each protein, and citrated blood samples were collected by tail transection after 30 minutes and 24 hours. Pharmacokinetics parameters including half-life and peak plasma concentration were determined using the graphing program Prism (Graphpad, San Diego, CA). In the hemophilia B mice, the clotting activity of infused F.IX was determined by one-stage modified aPTT assay.36
Purification of myotube-expressed recombinant F.IX from conditioned media Transduction of human myotubes with AAV-hF.IX at an MOI of 10 000 resulted in the secretion of 200 to 300 ng F.IX/mL per 24 hours. Note that at this MOI, nearly all cells in culture are transduced (Figure 1). Purification of recombinant F.IX from conditioned media is often achieved using a conformation-specific antibody37 that allows recovery of only the fully carboxylated species. In this case, however, we wanted to recover all species secreted from the myotubes, without regard to the efficiency with which posttranslational modifications had been completed. We therefore used as an initial step binding to and elution from a Q-Sepharose column. Ion exchange chromatography can be used to purify fully modified F.IX if a calcium gradient is used for the elution step,38 but our method used sodium chloride elution without a calcium gradient. Using plasma-derived F.IX, we showed that this step allows recovery of 89% of plasma-derived F.IX. Using the same strategy, 83% of myotube-synthesized factor IX was recovered from the starting material. Moreover, 10% of the starting material of both proteins was recovered when the flow-through fraction from the first binding step was reloaded onto a new Q-Sepharose column. Thus, almost 90% of myotube-synthesized F.IX and plasma-derived F.IX in the crude culture media can be recovered from the first column step.
The next step in the purification makes use of a monoclonal
antibody to the heavy chain of human F.IX (9EA). This monoclonal antibody was chosen specifically because the heavy chain has relatively few post-translational modifications. This strategy permits the recovery of 48% of F.IX from conditioned medium (Table
1).
The myotube-synthesized F.IX purified from conditioned medium migrates
as a single band with an apparent molecular weight (Mol wt) of 55 000
(Figure 2A). It migrates in a fashion
similar to HepG2 cell-synthesized F.IX (lane 3), and to Mononine
(Armour), a commercially available plasma-derived F.IX (lane 4).
Immunoblotting identifies these proteins as human F.IX (Figure 2B).
Specific activity of the purified myotube-synthesized F.IX Specific activity was determined on myotube-synthesized F.IX purified from 3 separate transduction experiments using an MOI of 10 000. These all showed specific activity approximately equal to that of plasma-derived F.IX (Table 2). The average of the 3 experiments yielded a specific activity of 180 U/mg,46 similar to the value of 200 U/mg, the published value for plasma-derived F.IX.39
Specific activity of myotube-synthesized F.IX in conditioned medium at different MOIs Triplicate plates of human myotubes were transduced with AAV-hF.IX at a range of MOIs from 5000 to 80 000. The median specific activity was 177 ± 45 U/mg, with a range from 108 to 233 U/mg). A progressive reduction in the specific activity was observed at MOIs greater than 20 000 (Table 3), suggesting that the capacity for some critical posttranslational modification is exceeded at high MOI.
Additional evidence of the activity of the myotube-synthesized F.IX was obtained by determining the inhibitory effect of the monoclonal antibody FXOO8. This antibody binds to the heavy chain of factor IXa and impairs its interaction with factor VIIIa, resulting in a reduced activation of factor X.40 Factor IX clotting activity measured using the aPTT on myotube-conditioned media ranged from 6.4% to 10% of normal plasma but decreased to values less than 1% after the incubation of conditioned media with an anti-human factor IX monoclonal antibody (data not shown). N-terminal sequence analysis N-terminal amino acid sequence analysis of the single band shown in Figure 2A (myotube-synthesized F.IX) demonstrates that the band contains a single species with a sequence identical to that of mature plasma-derived F.IX (Table 4). Thus the signal sequence and the propeptide are accurately and efficiently removed.
-carboxylated glutamic acid residues. Using chemical Gla analysis, myotube-synthesized F.IX has 10.5 Gla residues/mol F.IX, which is
slightly lower than 12 Gla residues/mol detected in 2 plasma-derived F.IX samples analyzed as controls. These data are consistent with those
obtained on N-terminal sequence analysis, in which the automated sequencing through residue 37 shows the low yields typically seen for
-carboxylated glutamic acid (Gla) residues (Table 4). Glu 7, 8, 15, 17, 20, 21, 26, 27, 30, 33, and 36 are each less than 10% of the yield
at the previous and subsequent cycles. Only a single -carboxylated
residue, Gla 40, was not assessed by N-terminal sequencing. The results
are in agreement with those reported for plasma-derived F.IX and
suggest that these Gla residues are more than 90% carboxylated.
Carbohydrate analysis As noted earlier, F.IX contains both N- and O-linked oligosaccharide residues. Sites of O-linked glycosylation within liver-synthesized F.IX have been identified at residues Ser 53, Ser 61, Thr 159, Thr 169, Thr 172, and Thr 179,28,41 but the function of these residues remains unknown. The O-linked sites are not easily analyzed by enzymatic release because O-glycanase digestion requires an -GalNAc linkage, nor are they readily examined using
oligosaccharide profiling because enzymatic removal and fluorescent
labeling of O-linked residues are inefficient processes that require
large amounts of starting material to yield detectable signal. Given the absence of a known function and the technical difficulties of
O-linked analysis, we have confined our analysis to the N-linked residues. Enzymatic digestion of myotube-synthesized F.IX by
N-glycosidase F results in a decrease in apparent molecular weight
(Figure 3), consistent with the removal
of N-linked carbohydrate. This result is identical to that seen with
plasma-derived F.IX or F.IX purified from AAV-hF.IX-transduced
HepG2 cells.
A more detailed analysis of N-linked carbohydrate residues was carried
out using oligosaccharide profiling, in which oligosaccharide residues
are cleaved off, labeled with a fluorophore, and analyzed electrophoretically33,42 (Figure
4). Positions of the oligosaccharides in
each lane of Figure 4 are determined relative to the glucose ladder in
lane 1, and the quantification of oligosaccharides is based on the
relative fluorescent intensity compared to that of 100 pmol
maltotetrose standard band (G4) shown in lane 4.42 A
well-characterized control glycoprotein, trypsin inhibitor, was treated
identically to the control for enzymatic activity and fluorescent
labeling (Figure 4, lane 5). Oligosaccharide profiling indicates that,
though a number of the labeled oligosaccharide bands are similar in
abundance and in position in a comparison of profiles for
myotube-synthesized versus plasma-derived F.IX, a number of differences
are detected (Figure 4). As an additional profiling step, labeled
oligosaccharides were incubated with neuraminidase to release sialic
acid. In carbohydrate electrophoresis, separation of complex
oligosaccharides is influenced both by negative charges contributed by
sialic acid and by the size (hydrodynamic volume) of the
oligosaccharide. Therefore, an oligosaccharide containing sialic acids
can migrate faster than a smaller oligosaccharide without sialic
acids.33,42 Thus, removal of sialic acid from individual
oligosaccharide bands results in a net upward shift of bands due to a
combination of the loss of charge and mass (Figure 5). Again, this suggests that many, but
not all, bands are identical because each band represents a unique
oligosaccharide. Thus, though both proteins exhibit a complex pattern
of N-glycosylation with many similarities, the patterns are not
identical.
Tyrosine sulfation The tyrosine residue at position 155 is sulfated in plasma-derived F.IX. Using in vitro incorporation of labeled 35S-sulfate in HepG2 cells (to model liver synthesis) and myotubes, we sought to determine whether this residue was also sulfated in myotube-synthesized F.IX. Labeling of cells with 35S-methionine allows normalization for total protein synthesis from one experiment to another (myotube vs HepG2 cell synthesized); the 35S-H2SO4 should reflect sulfation of the tyrosine at 155 after the contribution from sulfation in N-linked carbohydrate residues is removed34,43,44 by N-glycosidase F treatment (Figure 6). Assuming that HepG2 cells model hepatocyte synthesis and that the sulfate label in O-linked carbohydrate residues is identical in myotube- and HepG2 cell-synthesized F.IX, the results show that myotube-synthesized F.IX is minimally sulfated (1.2%) at Tyr 155 compared to HepG2 cell-synthesized F.IX.
Serine phosphorylation A monoclonal antibody against phosphoserine residues permits relative quantitation of serine phosphorylation once carbohydrate groups (located in close proximity to Ser 158 resulting in steric hindrance of the antibody) have been removed. Analysis was performed on both purified plasma-derived F.IX and purified myotube-synthesized F.IX. The results show that 15 ± 3 ng/mL of 230 ± 80 ng/mL myotube-synthesized F.IX is phosphorylated, whereas 195 ± 6 ng/mL of 495 ± 15 ng/mL of plasma-derived F.IX is phosphorylated. Note that the differing affinities of the 2 antibodies preclude calculation of the percentage of F.IX that is phosphorylated but allow determination of relative levels of serine phosphorylation of myotube-synthesized F.IX (16%) compared to plasma-derived F.IX.Myotube-synthesized F.IX is biologically active in vivo but has a lower recovery than plasma-derived F.IX We measured recovery, half-life, and biologic activity of myotube-synthesized F.IX by conducting the appropriate pharmacokinetic studies in hemophilic and normal mice. To determine recovery and half-life, normal mice were infused with 2 µg plasma-derived (n = 4 mice), CHO cell-synthesized (n = 3 mice), or myotube-synthesized (n = 3 mice) F.IX. In humans and animals, F.IX disappearance from plasma can be described in terms of a 2-component model, with a rapid disappearance (termed), corresponding to distribution into the
tissues, followed by a much slower decay (termed ), thought to
correspond to F.IX catabolism.45 The t1/2 for
plasma-derived F.IX was 2.19 hours, and for myotube-synthesized F.IX it
was 2.58 hours. The CHO-synthesized F.IX (Benefix; Genetic Institute)
showed the longest half-life, 4.2 hours (n = 3 mice) (Figure
7). These values are similar to those
obtained in dogs after the infusion of either CHO cell-synthesized or
plasma-derived F.IX46 that is, the 40% recovery after the
injection of protein was higher for plasma-derived F.IX (Figure 7) than
the 18% myotube- or CHO cell-synthesized F.IX. Factor IX clotting
activity assayed by modified aPTT was carried out in 12 hemophilic
animals after the infusion of F.IX preparations (10 µg/animal). In
all animals the aPTT shortened into the normal range (22-39 seconds)
after F.IX injection. Before and 30 minutes after infusion, aPTTs were
70.1 ± 11 seconds to 32.7 ± 1.3 seconds for plasma-derived F.IX,
69 ± 17 seconds to 32.0 ± 2.4 seconds for CHO cell-synthesized
F.IX, and 68.55 ± 4.5 to 33.1 ± 1.0 seconds for
myotube-synthesized F.IX. Values were similar at 24 hours, within the
normal range of 22 to 39 seconds, reflecting the high initial
dose.
Previous work has shown that biologically active F.IX can be synthesized in a variety of tissues, including skeletal muscle cell.47-49 In addition to demonstrating the biologic activity of muscle-synthesized protein, however, we wanted to conduct detailed biochemical characterization because the nature of the posttranslational modifications can influence the recovery of the protein28 and, theoretically, the immunogenicity.50 Short of isolating muscle-synthesized F.IX from the plasma of treated human subjects, there is no straightforward method for obtaining F.IX synthesized in skeletal muscle because it is not possible to maintain mature myocytes in culture. However, myoblasts can be differentiated to myotubes in tissue culture, and these faithfully model many of the characteristics of mature skeletal muscle. In our experimental system, human F.IX was purified from conditioned medium using an ion exchange step followed by an immuno-affinity column with a monoclonal antibody to the heavy chain. Usual procedures for recovering recombinant F.IX from conditioned medium make use of antibodies to the light chain.37 We wanted to avoid this strategy because our goal was to recover material representative of all species of recombinant F.IX in the conditioned medium, not simply that fraction that was correctly posttranslationally modified. Based on a determination of F.IX content in conditioned medium and total amounts of purified protein isolated, our recovery of F.IX from conditioned medium was approximately 50%. The purified myotube-synthesized F.IX yielded a single band on SDS-PAGE that migrated in a fashion identical to that of plasma-derived F.IX, and N-terminal sequence analysis of the recombinant F.IX was identical to that of mature plasma-derived F.IX. The requirement for cleavage of the propeptide of the F.IX is critical for functional activity.51 Although the enzyme responsible for the proteolytic cleavage is not identified with certainty, a candidate enzyme, PACE/Furin, can process the pro-FIX precursor when F.IX is overexpressed in a CHO cell system.52 The level of expression of PACE/Furin in skeletal muscle is unknown, but within the limits of F.IX expression in this study (range, 200-300 ng/mL per 24 hours), no abnormality was found in propeptide cleavage based on N-terminal sequence analysis of purified myotube-synthesized F.IX. These data suggest that the signal sequence and propeptide of precursor F.IX are accurately and efficiently removed in human myotubes. The direct In previous work54 we have demonstrated that the
Addition of N-linked oligosaccharides often is an obligatory event for the folding and assembly of polypeptides.50 N-glycosylation can be required for biologic activity and for the efficient transport of glycoproteins through the secretory pathway. In addition, it may influence half-life in the circulation.28,50 Sixty percent of the carbohydrate in factor IX is at N-linked sites located within the activation peptide.55 We analyzed the glycosylation of the myotube-synthesized factor IX using enzymatic cleavage of N-linked glycans and oligosaccharide profiling. Band patterns after enzymatic removal of N-linked oligosaccharides or of sialic acid residues suggest a similar amount of carbohydrate in myotube-synthesized F.IX and plasma-derived F.IX, though the patterns are not identical. In general, oligosaccharide profiling of plasma-derived F.IX is more heterogeneous because the product is derived from many donors. Some of the differences in glycosylation between myotube- and hepatocyte-synthesized F.IX likely reflect simply differences in cell type, just as the differences in glycosylation between plasma-derived and recombinant F.IX reflect differences in both the species (human vs hamster) and the cell type.8,15 It is theoretically possible that a gene therapy approach could, through overexpression of the transgene, result in an abnormal glycosylation pattern, but there is no evidence that the cellular machinery for N-glycosylation can be saturated.28 In plasma-derived F.IX, tyrosine at position 155 is sulfated; in contrast, recombinant F.IX expressed in CHO cells8 and, as shown here, myotube-synthesized F.IX are inefficiently sulfated at Tyr 155. Whether these cells have the capacity for tyrosine sulfation is unknown. Recently, the enzymes that catalyze tyrosine sulfation, tyrosyl protein sulfotransferase (TPST), have been identified. Northern blot analysis demonstrates that levels of expression of both TPST 1 and TPST 2 transcripts in skeletal muscle are similar to those seen in liver, but the functional activity of these proteins is unknown.56-59 Reduced tyrosine sulfation is likely to decrease the recovery of F.IX in vivo.28,60 In agreement with these findings, we have shown that the recovery of myotube-synthesized F.IX and CHO-cell synthesized F.IX is substantially reduced compared to that of plasma-derived F.IX. Finally, serine phosphorylation at position 158 was also evaluated. The levels of serine phosphorylation in myotube-synthesized F.IX are only 16% of those of plasma-derived F.IX, which reflects a limited capacity of the muscle cells to perform this modification. According to published data, CHO-derived recombinant F.IX contains no phosphorylation at this position, but no effect on the specific activity was observed.8 Thus, myotube-synthesized F.IX, like CHO-derived recombinant F.IX, is poorly phosphorylated at this residue, and, as has been observed with CHO-derived recombinant F.IX, this does not appear to affect specific activity. In summary, F.IX undergoes a series of complex post-translational modifications that are required for efficient secretion, normal recovery and half-life, and biologic activity. We have used a human myotube culture system to demonstrate that functional hF.IX can be produced in cells derived from skeletal muscle. Moreover, the detailed biochemical characterization of recombinant hFIX produced in myotubes demonstrates that these cells are able to perform the most important of the posttranslational modifications required for functional activity. Studies of recovery and half-life of myotube-synthesized F.IX in mice demonstrate reduced recovery but similar half-life compared to plasma-derived F.IX. Conclusions from these biochemical studies are also supported by studies in hemophilic dogs, in which shortening of clotting assays was demonstrated after the introduction of an AAV-F.IX vectors into skeletal muscle.25 Together the data presented here permit us to state with a reasonable degree of certainty that F.IX synthesized in myotubes has a biochemical profile and a biologic activity comparable to hepatocyte-synthesized F.IX and should thus result in correction of the hemostatic defect in human hemophilia B.
Submitted December 9, 1999; accepted September 12, 2000.
Supported by National Institutes of Health grants RO1 HL 53668 and RO1 HL 48322.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Katherine A. High, Division of Hematology, The Children's Hospital of Philadelphia, 310A Abramson Research Center, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104.
1.
Eyster ME, Gill FM, Blatt PM, et al.
Central nervous system bleeding in hemophiliacs.
Blood.
1978;51:1179-1188 2. Ludlam CA. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia: Executive Committee of the UKHCDO: United Kingdom Haemophilia Centre Directors' Organisation. Lancet. 1997;350:1704[Medline] [Order article via Infotrieve]. 3. Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang. 1993;64:197-203[Medline] [Order article via Infotrieve].
4.
Bray GL, Gomperts ED, Courter S, et al.
A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A.
Blood.
1994;83:2428-2435
5.
Lusher JM, Arkin S, Abildgaard CF, Schwartz RS.
Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A.
N Engl J Med.
1993;328:453-459
6.
Parks WP, Boucher DW, Melnick JL, Taber LH, Yow MD.
Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses.
Infect Immun.
1970;2:716-722
7.
Ragni MV, Tegtmeier GE, Levy JA, et al.
AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations.
Blood.
1986;67:592-595 8. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78:261-265[Medline] [Order article via Infotrieve].
9.
Lofqvist T, Nilsson IM, Berntorp E, Pettersson H.
Haemophilia prophylaxis in young patients 10. Nilsson I. Experience with prophylaxis in Sweden. Semin Hematol. 1993;30:16-19[Medline] [Order article via Infotrieve].
11.
Troisi CL, Hollinger FB, Hoots WK, et al.
A multicenter study of viral hepatitis in a United States hemophilic population.
Blood.
1993;81:412-418
12.
Diamondsstone LS, Blakley SA, Rice JC, Clark RA, Goedert JJ.
Prognostic factor for all-cause mortality among hemophiliacs infected with human immunodeficiency virus.
Am J Epidemiol.
1995;142:304-313 13. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350:1425-1431[CrossRef][Medline] [Order article via Infotrieve].
14.
Dhawan J, Pan LC, Pavlath GK, Travis MA, Lanctot AM, Blau HM.
Systemic delivery of human growth hormone by injection of genetically engineered myoblast.
Science.
1991;254:1509-1512 15. Fisher KJ, Gao G-P, Weitzman MD, DeMatteo R, Burda JF, Wilson JF. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol. 1996;70:520-532[Abstract]. 16. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70:8098-8108[Abstract]. 17. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med. 1997;3:306-312[CrossRef][Medline] [Order article via Infotrieve].
18.
Mir LM, Bureau MF, Gehl J, et al.
High-efficiency gene transfer into skeletal muscle mediated by electric pulse.
Proc Natl Acad Sci U S A.
1999;96:4262-4267
19.
Murphy JE, Zhou S, Giese K, Williams LT, Escobedo JA, Dwarki VJ.
Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin.
Proc Nat Acad Sci U S A.
1997;94:13921-13926
20.
Tripathy SK, Goldwasser E, Lu MM, Barr E, Leiden JM.
Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus.
Proc Natl Acad Sci U S A.
1996;91:11557-11561
21.
Russell DW, Miller AD, Alexander JE.
Adeno-associated virus vectors preferentially transduce cells in S phase.
Proc Natl Acad Sci U S A.
1994;91:8915-8919 22. Muzcyzka N. Use of adeno-associated virus as a general transduction vector in mammalian cells. Curr Topics Microbiol Immunol. 1992;158:97-129[Medline] [Order article via Infotrieve]. 23. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 1991;10:3941-3950[Medline] [Order article via Infotrieve].
24.
Herzog RW, Hagstrom JN, Kung Z-H, et al.
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.
Proc Natl Acad Sci U S A.
1997;94:5804-5809 25. Herzog RW, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med. 1999;5:56-62[CrossRef][Medline] [Order article via Infotrieve].
26.
Evans JP, Watzke HH, Ware JL, Stafford DW, High KA.
Molecular cloning of cDNA encoding canine factor IX.
Blood.
1989;74:207-212 27. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988;53:505-518[CrossRef][Medline] [Order article via Infotrieve]. 28. Kaufman RJ. Posttranslational modifications required for coagulation factor secretion and function. Thromb Haemost. 1998;79:1068-1079[Medline] [Order article via Infotrieve].
29.
Nakai H, Herzog R, Hagstrom JN, et al.
AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver.
Blood.
1998;91:4600-4607 30. Matsushita T. Adeno-associated virus vector can be efficiently produced without helper virus. Gene Ther. 1998;5:938-945[CrossRef][Medline] [Order article via Infotrieve]. 31. Heiman-Patterson T, Krupa T, Thompson P, Nobile-Orazio E, Tahmoush AJ, Shy ME. Anti-GM1/DG1b M-proteins damage human spinal cord neurons co-cultured with muscle. J Neurol Sci. 1993;120:38-43[CrossRef][Medline] [Order article via Infotrieve].
32.
Walter J, You Q, Hagstrom JN, Sands M, High KA.
Successful expression of human factor IX following repeat administration of adenoviral vector in mice.
Proc Natl Acad Sci U S A.
1996;93:3056-3061 33. Starr CM, Masada RI, Hague C, et al. Fluorophore-assisted carbohydrate electrophoresis in the separation, analysis, and sequencing of carbohydrates. J Chromatogr A. 1996;720:295-321[CrossRef][Medline] [Order article via Infotrieve]. 34. Huttner WB. Determination and occurrence of tyrosine O-sulfate in proteins. Methods Enzymol. 1997;107:200-223. 35. Pittman DD, Wang JH, Kaufman RJ. Identification of functional importance of tyrosine sulfate residues within recombinant factor VIII. Biochemistry. 1992;31:3315-3325[CrossRef][Medline] [Order article via Infotrieve].
36.
Kung J, Hagstrom J, Cass D, et al.
Human F.IX corrects the bleeding diathesis of mice with hemophilia B.
Blood.
1998;91:784-790 37. Smith KJ, Ono K. Monoclonal antibodies to factor IX: characterization and use in immunoassays for factor IX. Thromb Res. 1984;33:211[CrossRef][Medline] [Order article via Infotrieve]. 38. Yan SCB, Razzano P, Chao YB, et al. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotech. 1990;8:655-661. 39. Bond M, Jankowski M, Patel H, et al. Biochemical characterization of recombinant factor IX. Semin Hematol. 1998;35:11-17[Medline] [Order article via Infotrieve].
40.
Bajaj SP, Rapaport SI, Maki SL.
A monoclonal antibody to factor IX that inhibits the factor VIII: Ca potentiation of factor X activation.
J Biol Chem.
1985;260:11574-11580 41. Bond MD, Huberty MC, Jankowski MA, Vath JE, Strang AM, Scoble HA. Identification of O-glycosylation, sulfation and phosphorylation sites in the activation peptide of human factor IX [abstract]. Blood. 1997;84:531a. 42. Masada RI, Hague C, Seid R, et al. Fluorophore-assisted carbohydrate electrophoresis (FACE) for determining the nature and consistency of recombinant protein glycosylation. Trends Glycosci Glycotechnol. 1995;34:133-147. 43. Dorner AJ, Kaufman RJ. Analysis of synthesis, processing, and secretion of proteins expressed in mammalian cells. Methods Enzymol. 1990;185:577-596[Medline] [Order article via Infotrieve]. 44. Kornfeld R, Kornfeld S. Assembly of aspargine-linked oligosaccharides. Ann Rev Biochem. 1985;54:631-664[CrossRef][Medline] [Order article via Infotrieve]. 45. Zauber NP, Levin J. Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP). Medicine. 1977;56:213-224[Medline] [Order article via Infotrieve]. 46. Schaub R, Garzone P, Bouchard P, et al. Preclinical studies of recombinant factor IX. Semin Hematol. 1998;35:28-32[Medline] [Order article via Infotrieve].
47.
Palmer TD, Thompson AR, Miller AD.
Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B.
Blood.
1989;73:438-445
48.
Yao S-N, Wilson JM, Nabel EG, Kurachi S, Hachiya HL, Kurachi K.
Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B.
Proc Natl Acad Sci U S A.
1991;88:8101-8105
49.
Yao SN, Kurachi K.
Expression of human factor IX in mice after injection of genetically modified myoblasts.
Proc Natl Acad Sci U S A.
1992;89:3357-3361 50. Graves DJ, Martin BL, Wang JH. Co- and post-translational modification of proteins, chemical principles and biological effects. New York: Oxford University Press; 1994.
51.
Giannelli F, Green PM, Sommer SS, et al.
Haemophilia B: database of point mutations and short additions and deletions. 7th ed.
Nucl Acids Res.
1997;25:133-135
52.
Wasley LC, Bristol JA, Kaufman RJ.
PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway.
J Biol Chem.
1993;268:8458-8465
53.
Gillis S, Furie BC, Furie B, et al.
54.
Wu S-M, Stafford DW, Frazier LD, et al.
Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase.
Blood.
1997;89:4058-4062 55. DiScipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest. 1978;61:1528-1538. 56. Niehrs C, Huttner WB. Purification and characterization of tyrosylprotein sulfotransferase. EMBO J. 1990;9:35-42[Medline] [Order article via Infotrieve].
57.
Beisswanger R, Corbeil D, Vannier C, et al.
Existence of distinct tyrosylprotein sulfotransferase genes: molecular characterization of tyrosylprotein sulfotransferase-2.
Proc Natl Acad Sci U S A.
1998;95:11134-11139
58.
Ouyang Y-B, Lane WS, Moore KL.
Tyrosylprotein sulfotransferase: purification and molecular cloning of an enzyme that catalyzes tyrosine O-sulfation, a common posttranslational modification of eukaryotic proteins.
Proc Natl Acad Sci U S A.
1998;95:2896-2901
59.
Ouyang Y-B, Moore KL.
Molecular cloning and expression of human and mouse tyrosylprotein sulfotransferase-2 and a tyrosylprotein sulfotransferase homologue in Caenorhabditis elegans.
J Biol Chem.
1998;273:24770-24774 60. Bond M, Jankowski MA, Huberty MC, Patel H, Scoble HA. Structural analysis of recombinant human factor IX [abstract]. Blood. 1994;84:194a.
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  D. E. Sabatino, C. F. Freguia, R. Toso, A. Santos, E. P. Merricks, H. H. Kazazian Jr, T. C. Nichols, R. M. Camire, and V. R. Arruda Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model Blood, November 12, 2009; 114(20): 4562 - 4565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Simioni, D. Tormene, G. Tognin, S. Gavasso, C. Bulato, N. P. Iacobelli, J. D. Finn, L. Spiezia, C. Radu, and V. R. Arruda X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) N. Engl. J. Med., October 22, 2009; 361(17): 1671 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Yang, J. Feng, W. Song, J. Wang, B. Tsai, Y. Zhang, W. A. Scaringe, K. A. Hill, P. Margaritis, K. A. High, et al. A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin PNAS, September 25, 2007; 104(39): 15394 - 15399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Atoda, E. Yokota, and T. Morita Characterization of a Monoclonal Antibody B1 That Recognizes Phosphorylated Ser-158 in the Activation Peptide Region of Human Coagulation Factor IX J. Biol. Chem., April 7, 2006; 281(14): 9314 - 9320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, E. Dobrzynski, A. Schlachterman, O. Cao, and R. W. Herzog Systemic protein delivery by muscle-gene transfer is limited by a local immune response Blood, June 1, 2005; 105(11): 4226 - 4234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Arruda, H. H. Stedman, T. C. Nichols, M. E. Haskins, M. Nicholson, R. W. Herzog, L. B. Couto, and K. A. High Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model Blood, May 1, 2005; 105(9): 3458 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schuettrumpf, R. W. Herzog, A. Schlachterman, A. Kaufhold, D. W. Stafford, and V. R. Arruda Factor IX variants improve gene therapy efficacy for hemophilia B Blood, March 15, 2005; 105(6): 2316 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Sabatino, E. Armstrong, S. Edmonson, Y.-L. Liu, M. Pleimes, J. Schuettrumpf, J. Fitzgerald, R. W. Herzog, V. R. Arruda, and K. A. High Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene Blood, November 1, 2004; 104(9): 2767 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chenuaud, T. Larcher, J. E. Rabinowitz, N. Provost, Y. Cherel, N. Casadevall, R. J. Samulski, and P. Moullier Autoimmune anemia in macaques following erythropoietin gene therapy Blood, May 1, 2004; 103(9): 3303 - 3304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Arruda, J. Schuettrumpf, R. W. Herzog, T. C. Nichols, N. Robinson, Y. Lotfi, F. Mingozzi, W. Xiao, L. B. Couto, and K. A. High Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1 Blood, January 1, 2004; 103(1): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Manno, A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B Blood, April 15, 2003; 101(8): 2963 - 2972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Favre, V. Blouin, N. Provost, R. Spisek, F. Porrot, D. Bohl, F. Marme, Y. Cherel, A. Salvetti, B. Hurtrel, et al. Lack of an Immune Response against the Tetracycline-Dependent Transactivator Correlates with Long-Term Doxycycline-Regulated Transgene Expression in Nonhuman Primates after Intramuscular Injection of Recombinant Adeno-Associated Virus J. Virol., October 11, 2002; 76(22): 11605 - 11611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Butenas, K. E. Brummel, R. F. Branda, S. G. Paradis, and K. G. Mann Mechanism of factor VIIa-dependent coagulation in hemophilia blood Blood, February 1, 2002; 99(3): 923 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. High Gene Transfer as an Approach to Treating Hemophilia Circ. Res., February 2, 2001; 88(2): 137 - 144. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
80°C.
